BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23692463)

  • 1. Immunologic microenvironment and personalized treatment in multiple myeloma.
    Rossi M; Botta C; Correale P; Tassone P; Tagliaferri P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S83-93. PubMed ID: 23692463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
    Amodio N; Di Martino MT; Neri A; Tagliaferri P; Tassone P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S125-37. PubMed ID: 23692413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy strategies in multiple myeloma.
    Bae J; Munshi NC; Anderson KC
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):927-43. PubMed ID: 25212890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biological insights and novel treatment strategies in multiple myeloma.
    Gentile M; Recchia AG; Mazzone C; Morabito F
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging pathways as individualized therapeutic target of multiple myeloma.
    Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for the treatment of multiple myeloma.
    Saini N; Mahindra A
    Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into therapeutic targets in myeloma.
    Anderson KC
    Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune defects in multiple myeloma].
    Shindo T; Kimura S
    Nihon Rinsho; 2015 Jan; 73(1):52-6. PubMed ID: 25626304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune alterations in malignant melanoma and current immunotherapy concepts.
    Shimanovsky A; Jethava A; Dasanu CA
    Expert Opin Biol Ther; 2013 Oct; 13(10):1413-27. PubMed ID: 23930800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells.
    Giuliani N; Airoldi I
    Clin Cancer Res; 2011 Nov; 17(22):6963-70. PubMed ID: 21880791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma: an update of developments in targeted therapy.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):379-89. PubMed ID: 15877532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
    Terpos E; Dimopoulos MA; Sezer O
    Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
    van de Donk NW; Kamps S; Mutis T; Lokhorst HM
    Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
    Lernoux M; Schnekenburger M; Dicato M; Diederich M
    Biochem Pharmacol; 2021 Jun; 188():114526. PubMed ID: 33741332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune regulation in multiple myeloma: the host-tumour conflict.
    Cook G; Campbell JD
    Blood Rev; 1999 Sep; 13(3):151-62. PubMed ID: 10527267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.